Literature DB >> 19245508

Statin pleiotropy against renal injury.

Michael S Kostapanos1, Evangelos N Liberopoulos, Moses S Elisaf.   

Abstract

Statins may exhibit significant renoprotective effects beyond their lipid-lowering capacity. Herein, the authors review data from human and animal models of renal disease as well as from studies in cultured renal cells with regard to extralipid renoprotective properties of statins. Statins may exert lipid-independent benefits against renal injury in experimental states of chronic or acute renal function impairment. These include diabetic and hypertensive glomerulosclerosis, autoimmune glomerulonephritis, ischemia/reperfusion-induced renal damage, and unilateral ureteral obstructive nephropathy. Also, statins, by reducing the synthesis of mevalonate products, inhibit the activation of Rho and Ras guanosine triphosphatases that may influence various signaling pathways involving renal inflammatory, fibrogenic, proliferative, and cell-death responses. Therefore, statins exert anti-inflammatory actions in renal tissue, prevent renal scarring, and diminish mesangial or other kidney cell-type proliferation while promoting mesangial cell apoptosis. Renal antioxidant effects with consequent endothelial function regulation of renal vasculature following statin treatment may also account for pleiotropic protection against renal injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19245508     DOI: 10.1111/j.1559-4572.2008.00052.x

Source DB:  PubMed          Journal:  J Cardiometab Syndr        ISSN: 1559-4564


  16 in total

1.  Statin use associates with a lower incidence of acute kidney injury after major elective surgery.

Authors:  Amber O Molnar; Steven G Coca; Phillip J Devereaux; Arsh K Jain; Abhijat Kitchlu; Jin Luo; Chirag R Parikh; J Michael Paterson; Nausheen Siddiqui; Ron Wald; Michael Walsh; Amit X Garg
Journal:  J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 10.121

2.  JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses.

Authors:  Michael S Kostapanos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2011-07-26

Review 3.  Renoprotective approaches and strategies in acute kidney injury.

Authors:  Yuan Yang; Meifang Song; Yu Liu; Hong Liu; Lin Sun; Youming Peng; Fuyou Liu; Manjeri A Venkatachalam; Zheng Dong
Journal:  Pharmacol Ther       Date:  2016-04-22       Impact factor: 12.310

4.  Statins and mortality: the untold story.

Authors:  Michael S Kostapanos; Moses S Elisaf
Journal:  Br J Clin Pharmacol       Date:  2017-03-17       Impact factor: 4.335

Review 5.  Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Authors:  Michael S Kostapanos; Christos V Rizos; Moses S Elisaf
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

6.  Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Jelena Klawitter; Kim McFann; Alexander T Pennington; Wei Wang; Jost Klawitter; Uwe Christians; Robert W Schrier; Berenice Gitomer; Melissa A Cadnapaphornchai
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-29       Impact factor: 8.237

7.  Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.

Authors:  Melissa A Cadnapaphornchai; Diana M George; Kim McFann; Wei Wang; Berenice Gitomer; John D Strain; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

8.  Pleiotropic effects of the HMG-CoA reductase inhibitors.

Authors:  Christos G Mihos; Orlando Santana
Journal:  Int J Gen Med       Date:  2011-04-04

9.  Protective Effects of Simvastatin, a Lipid Lowering Agent, against Oxidative Damage in Experimental Diabetic Rats.

Authors:  Ahmed M Mohamadin; Ahmed A Elberry; Hala S Abdel Gawad; Gehan M Morsy; Fahad A Al-Abbasi
Journal:  J Lipids       Date:  2011-12-06

Review 10.  The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review.

Authors:  Pavan Malur; Arthur Menezes; James J DiNicolantonio; James H O'Keefe; Carl J Lavie
Journal:  Mo Med       Date:  2017 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.